Skip to content

Neurocrine Biosciences NBIX Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin393.6%+0.2pp393.4%+1.4pp392%-2.3pp394.3%-1.0pp
Operating margin82.4%-16.4pp98.8%+56.8pp42%
Net margin59.2%-7.1pp66.4%+27.9pp38.5%+15.4pp23.1%-101pp
Returns
Return on equity57.2%-7.1pp64.2%+25.8pp38.4%+16.3pp22.1%-104pp
Return on invested capital51.5%-17.8pp69.3%+38.3pp31%
Efficiency
Asset turnover2.7×0.0×2.8×0.0×2.8×+0.2×2.6×+0.1×
Liquidity
Current ratio13.1×-1.4×14.5×+3.2×11.2×-1.5×12.8×-6.6×
Leverage
Debt-to-equity0.7×+0.1×0.6×0.0×0.6×0.0×0.5×+0.1×
Net debt / EBITDA0.8×+0.2×0.6×-0.7×1.2×
Per Share
Book value per share$112.46+14.5%$98.22+26.3%$77.74+25.4%$62.01+16.6%
Valuation
Market capitalization$51.78B-2.2%$52.94B+22.9%$43.09B+8.0%$39.89B+11.9%
Price / earnings134.6×-13.8×148.3×-168×316.3×-504×820.6×+669×
Price / sales19.8×-4.7×24.5×-0.3×24.7×-4.9×29.6×-3.8×
Price / book18×-2.8×20.9×-1.3×22.2×-4.1×26.3×-1.2×
EV / EBITDA91.9×-3.8×95.7×-123×218.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Neurocrine Biosciences's profit margins?
Neurocrine Biosciences (NBIX) runs a 98.2% gross margin and a 25.4% operating margin, with a 21.6% net margin.
Where do Neurocrine Biosciences's ratios come from?
Every ratio is computed from Neurocrine Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.